Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.81 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.81 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.81 |
| ▸ | MAPT | P10636 | 4/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.81 |
| ▸ | MEN1 | O00255 | 2/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.81 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.79 |
| ▸ | CA12 | O43570 | 2/20 | 0.79 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 0.79 |
| ▸ | CA4 | P22748 | 2/20 | 0.79 |
| ▸ | CA7 | P43166 | 2/20 | 0.79 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.79 |
| ▸ | TTR | P02766 | 2/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pinocembrin SCHEMBL3437711 | 0.96 | CYP19A1 (0.88) | CYP19A1CYP3A4HSD17B10CYP1A1CYP1A2 | |
| Pinocembrin SCHEMBL17651823 | 0.93 | CYP19A1 (0.81) | CYP19A1CYP3A4HSD17B10CYP1A1CYP1A2 | |
| Eriodictyol SCHEMBL3438669 | 0.92 | CYP19A1 (0.78) | CYP19A1CYP3A4HSD17B10CYP1A1CYP1A2 | |
| Naringenin SCHEMBL72954 | 0.91 | CYP19A1 (0.81) | CYP19A1CYP3A4HSD17B10CYP1A1CYP1A2 | |
| (R)-Pinocembrin SCHEMBL10080882 | 0.90 | CYP19A1 (1.00) | CYP19A1CYP3A4HSD17B10CYP1A1CYP1A2 | |
| Pinocembrin SCHEMBL291899 | 0.90 | CYP19A1 (1.00) | CYP19A1CYP3A4HSD17B10CYP1A1CYP1A2 | |
| Pinocembrin SCHEMBL30186539 | 0.90 | CYP19A1 (1.00) | CYP19A1CYP3A4HSD17B10CYP1A1CYP1A2 | |
| Pinocembrin SCHEMBL10026578 | 0.90 | CYP19A1 (1.00) | CYP19A1CYP3A4HSD17B10CYP1A1CYP1A2 | |
| Isosakutanetin SCHEMBL2146746 | 0.89 | CYP1A1 (0.82) | CYP19A1CYP3A4HSD17B10CYP1A1CYP1A2 | |
| Pinocembrin SCHEMBL2484359 | 0.89 | CYP19A1 (0.97) | CYP19A1CYP3A4HSD17B10CYP1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1067189-B1 | GENE ENCODING FLAVONE SYNTHASE | INTERNAT FLOWERS DEVELOPMENTS (AU) | 2007-08-29 | — | — | EP | claimed |
| CN-1942168-A | Composition for regulating the trophism of hair follicles and the cutaneous production of sebum and use thereof in androgenetic alopecia | GIULIANI SPA (IT) | 2007-04-04 | — | — | CN | claimed |
| EP-4373471-A1 | COMBINATION FOR USE FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA, CARDIOVASCULAR DISEASE AND METABOLIC SYNDROME | Meda Pharma S.p.A. (IT) | 2024-05-29 | — | — | EP | disclosed |
| CN-114555798-B | Biosynthesis of eriodictyol | 科纳根公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-117813079-A | Combination for the treatment of hypercholesterolemia, hyperlipidemia, cardiovascular diseases and metabolic syndrome | 美达制药股份公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-3927177-B1 | FLAVONOIDS AND ANIMAL HEALTH AND PERFORMANCE | HEALTHTECH BIO ACTIVES S L U (ES) | 2024-02-14 | — | — | EP | disclosed |
| CN-113265433-B | Bifunctional glycosyltransferase and application thereof | 中国科学院分子植物科学卓越创新中心 | 2023-12-26 | — | — | CN | disclosed |
| CN-113136373-B | Carbonoside glycosyltransferase and application thereof | 中国科学院分子植物科学卓越创新中心 | 2023-12-08 | — | — | CN | disclosed |
| CN-116999451-A | Application of naringin in preparation of cisplatin drug resistance drug for reversing ovarian cancer cell strain | 南昌大学第一附属医院 | 2023-11-07 | — | — | CN | disclosed |
| CN-116270591-A | Use of flavonoid compound | 重庆西南果品营养研究院 | 2023-06-23 | — | — | CN | disclosed |
| CN-116059198-A | Use of naringenin in preparation of preparation for preventing and/or treating radiation injury | 中国人民解放军陆军军医大学 | 2023-05-05 | — | — | CN | disclosed |
| US-20040029914-A1 | Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents | SRI INTERNATIONAL | 2004-02-12 | — | — | US | disclosed |
| US-20030229136-A1 | Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents | SRI INTERNATIONAL | 2003-12-11 | — | — | US | disclosed |
| WO-2003089423-A2 | NOVEL FLAVANOIDS AND CHALCONES AS CHEMOTHERAPEUTIC, CHEMOPREVENTIVE, AND ANTIANGIOGENIC AGENTS | SRI INTERNATIONAL (US) | 2003-10-30 | — | — | WO | disclosed |
| US-20030101477-A1 | Process for increasing the flavonoid content of a plant and plants obtainable thereby | CONOPCO, INC. | 2003-05-29 | — | — | US | disclosed |
| EP-1254960-A1 | A process for increasing the flavonoid content of a plant and plants obtainable thereby | UNILEVER PLC (GB) | 2002-11-06 | — | — | EP | disclosed |
| WO-2002057418-A2 | METHODS OF PRODUCING POLYKETIDE SYNTHASE MUTANTS AND COMPOSITIONS AND USES THEREOF | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2002-07-25 | — | — | WO | disclosed |
| EP-1161540-A1 | GENETIC MANIPULATION OF ISOFLAVONOIDS | THE SAMUEL ROBERTS NOBLE FOUNDATION, INC. (US) | 2001-12-12 | — | — | EP | disclosed |
| WO-2001007579-A2 | METHODS AND COMPOSITIONS FOR DETERMINING ENZYMATIC ACTIVITY | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2000053771-A1 | GENETIC MANIPULATION OF ISOFLAVONOIDS | THE SAMUEL ROBERTS NOBLE FOUNDATION, INC. (US) | 2000-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029914-A1 | Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents | FLT1, VEGFA, FLT4 | CYP19A1 151/4885CYP3A4 261/4885HSD17B10 374/4885 |
| US-20030229136-A1 | Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents | FLT1, VEGFA, FLT4 | CYP19A1 132/4885CYP3A4 336/4885HSD17B10 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.